403985-96-6

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-(triphenylmethoxy)-3-buten-2-ol is used as an intermediate in the synthesis of pharmaceuticals due to its versatile nature and ability to be used in the production of various drugs.
Used in Agrochemical Industry:
(S)-1-(triphenylmethoxy)-3-buten-2-ol is used as a building block in the development of agrochemicals, contributing to the creation of effective and targeted products for agricultural applications.
Used in Fine Chemicals Industry:
(S)-1-(triphenylmethoxy)-3-buten-2-ol is used as a versatile intermediate in the production of fine chemicals, where its unique structure and reactivity are harnessed to create high-quality specialty products.
Used in Material Development:
(S)-1-(triphenylmethoxy)-3-buten-2-ol has potential applications in the development of new materials, where its unique properties can be utilized to create innovative and improved materials for various industries.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
(S)-1-(triphenylmethoxy)-3-buten-2-ol is used as a chiral auxiliary in asymmetric synthesis, playing a crucial role in the production of enantiomerically pure compounds, which are essential in various chemical and pharmaceutical applications.

Upstream product

• 2181-42-2 trimethylsulphonium iodide 
• 129940-50-7 (S)-tritylglycidol 
• 76-83-5 trityl chloride 
• 62214-39-5 (2S)-but-3-ene-1,2-diol 
• 949583-79-3 (E)-methyl (4-(trityloxy)but-2-en-1-yl)carbonate 

Downstream Products

• 1333501-63-5 C₂₄H₂₁N₃O₃ 
• 1262803-48-4 N-[(4aR,5S,7aS)-7a-(2-fluorophenyl)-5-trityloxy-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-yl]benzamide 
• 1174321-94-8 (3aR,4S,6aS)-6a-(2-fluorophenyl)-4-trityloxymethyltetrahydrofuro[3,4-c]isoxazole 
• 1174321-92-6 ((S)-1-trityloxymethylallyloxy)acetaldehyde oxime 
• 1174321-96-0 1-benzoyl-3-[(3S,4R,5S)-3-(2-fluorophenyl)-4-hydroxymethyl-5-trityloxymethyl-tetrahydrofuran-3-yl]thiourea 
• 1174321-95-9 [(2S,3R,4S)-4-amino-4-(2-fluorophenyl)-2-trityloxymethyl-tetrahydrofuran-3-yl]methanol 
• 1174321-93-7 (3aR,4S)-4-((trityloxy)methyl)-3,3a,4,6-tetrahydrofuro[3,4-c]isoxazole 
• 1174321-91-5 ethyl ((S)-1-trityloxymethylallyloxy)acetate 
• 602326-54-5 1,4-anhydro-2-azido-2-deoxy-5-O-trityl-D-arabino-pentitol 

Relevant academic research and scientific papers

Efficient Method for the Synthesis of Amino-1,3-Oxazines from Thioureas

The synthesis of a subtype-selective inhibitor BACE-1 inhibitor is presented. One of the key transformations in this sequence is the conversion of a thiourea to the bicyclic 1,3-aminooxazine. This article outlines the development and application of this method to the target molecule as well as further exploration of its scope and mechanism.

COMBINATION THERAPY OF BACE-1 INHIBITOR AND ANTI-N3PGLU ABETA ANTIBODY

The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula or a pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-N3pGlu Abeta antibody selected from the group consisting of hE8L, B12L, R17L, Antibody I, and Antibody II.

COMBINATION THERAPY

The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula (I):or a pharmaceutically acceptable salt thereo

4,4A,5,7-TETRAHYDRO-3H-FURO[3,4-B]PYRIDINYL COMPOUNDS

The present invention relates to 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compound inhibitors of beta-site APP-cleaving enzyme having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The invention is also dir

N-[3-[2-AMINO-5-(1,1-DIFLUOROETHYL)-4,4A,5,7-TETRAHYDROFURO[3,4-D][1,3]OXAZIN-7A-YL]-4-FLUORO-PHENYL]-5-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE AND ITS (4AR,5S,7AS) ISOMER AS A SELECTIVE BACE1 INHIBITOR FOR TREATING E.G. ALZHEIMER'S DISEASE

The present invention provides N-[3-[2-Amino-5-(1,1-difluoroethyl) -4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5- (trifluoromethyl)pyridine-2-carboxamide, i.e. the compound of Formula I: [Formula should be inserted here] or a pharma

TETRAHYDROFURANE-FUSED AMINOHYDROTHIAZINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.

SELECTIVE BACE1 INHIBITORS

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

Enantio- and regioselective iridium-catalyzed allylic hydroxylation

The first enantioselective allylic hydroxylation to prepare branched allylic alcohols directly is described. Bicarbonate was used as nucleophile in conjunction with new single component Ir-catalysts, which are stable to air and water. Excellent regio- and

FUSED AMINODIHYDRO-OXAZINE DERIVATIVES

A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

Synthesis and stereospecificity of 4,5-disubstituted oxazolidinone ligands binding to T-box riboswitch RNA

The enantiomers and the cis isomers of two previously studied 4,5-disubstituted oxazolidinones have been synthesized, and their binding to the T-box riboswitch antiterminator model RNA has been investigated in detail. Characterization of ligand affinities and binding site localization indicates that there is little stereospecific discrimination for binding antiterminator RNA alone. This binding similarity between enantiomers is likely due to surface binding, which accommodates ligand conformations that result in comparable ligand-antiterminator contacts. These results have significant implications for T-box antiterminator-targeted drug discovery and, in general, for targeting other medicinally relevant RNA that do not present deep binding pockets.